GeneDx Holdings Corp. (NASDAQ:WGS) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 347.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,072 shares of the company's stock after buying an additional 52,843 shares during the quarter. New York State Common Retirement Fund owned approximately 0.25% of GeneDx worth $5,232,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in WGS. Fred Alger Management LLC purchased a new position in GeneDx during the 3rd quarter valued at about $16,731,000. Geode Capital Management LLC increased its position in GeneDx by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after purchasing an additional 30,379 shares during the period. State Street Corp increased its position in GeneDx by 18.3% during the 3rd quarter. State Street Corp now owns 314,914 shares of the company's stock valued at $13,365,000 after purchasing an additional 48,735 shares during the period. Zweig DiMenna Associates LLC purchased a new position in GeneDx during the 4th quarter valued at about $23,788,000. Finally, Point72 Asset Management L.P. grew its position in shares of GeneDx by 87.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 293,671 shares of the company's stock worth $12,463,000 after buying an additional 136,926 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

GeneDx Trading Down 8.2 %

Shares of WGS traded down $8.47 during mid-day trading on Monday, reaching $94.38. The stock had a trading volume of 1,029,119 shares, compared to its average volume of 592,448. The business's fifty day moving average is $81.14 and its 200 day moving average is $65.66. GeneDx Holdings Corp. has a 52-week low of $7.72 and a 52-week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -48.25 and a beta of 2.01.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on WGS shares. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, GeneDx currently has an average rating of "Moderate Buy" and a consensus price target of $72.33.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 3,661 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $279,590.57. Following the transaction, the chief executive officer now directly owns 62,897 shares in the company, valued at $4,803,443.89. This represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 1,430 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20. Following the transaction, the chief financial officer now owns 26,770 shares in the company, valued at approximately $2,035,590.80. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 127,321 shares of company stock worth $11,315,903 over the last three months. Insiders own 27.30% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.